Mark Frohlich
Mark Frohlich, MD
Indapta Therapeutics
Adrian Woolfson
Adrian Woolfson, PhD
Co-founder, Exec. Chairman, and President
Parameswaran Hari
Parameswaran Hari
Chief Development Officer
Obsidian Therapeutics

Broadcast Date: 

  • Time: 

Several cell therapies have received approval from the U.S. Food and Drug Administration and there is significant excitement about the potential of these treatments to revolutionize clinical outcomes. Although CAR-T therapies have gained a lot of attention for their success in treating various cancers, there is a broader landscape of promising cell therapies being developed to address a range of diseases. That list includes natural killer cell-based therapies which leverage the power of the natural killer cells to recognize and destroy abnormal cells in both solid and hematological malignancies. Other therapy strategies leverage immune cells such as tumor-infiltrating lymphocytes and lymphokine-activated killer cells which studies have demonstrated can induce tumor regression in cancers like melanoma and glioblastoma.

In this GEN Keynote webinar, our experts will discuss emerging cell therapies other than CAR-T. They share examples from their own work including recent advances in the development of NK-based cell therapies for cancers like multiple myeloma and sarcoma. They’ll also discuss challenges and concerns regarding CAR-T based cell therapies as well as applications of cell therapies that go beyond cancer for conditions such as degenerative disorders and autoimmune diseases.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.

Produced with support from:

Qiagen logo

The post The Evolving Landscape of Cell Therapies Beyond CAR-T appeared first on GEN – Genetic Engineering and Biotechnology News.